Poletti ED, Muñoz SMR, Llamas EG

Idioma: Español
Referencias bibliográficas: 32
Paginas: 210-216
Archivo PDF: 238.92 Kb.

RESUMEN

La psoriasis, enfermedad inflamatoria de causa desconocida y multifactorial, es una dermatosis inflamatoria, frecuente y de curso crónico. Su gran variabilidad clínica y evolutiva, los antecedentes personales del paciente, el tipo y la extensión de las lesiones determinan su gravedad. Con la nueva forma de abordar los casos, mediante un enfoque multidisciplinario que describe con precisión los múltiples factores que intervienen en su agravamiento y pronóstico, se pretende esclarecer cada vez más tempranamente su relación con el síndrome metabólico (obesidad, diabetes mellitus, hipertensión arterial, dislipidemia, etc.), para así definir su influencia en mejor calidad de vida.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bolognia JL, Jorizzo JL , Rapini RP, editors. Dermatology. 2nd ed. London: Mosby-Elsevier, 2008;pp:115-35.

2. Callen JP, Jorizzo JL , Bolognia JL, Piette WW, Zone JJ, editors. Dermatological signs of internal disease. 3rd ed. Philadelphia: WB Saunders, 2003;pp:33-37.

3. Lebwohl MG. The skin and systemic disease: a color atlas and text. 2nd ed. London: Chrchilll Livigstone, 2004;pp:21-26.

4. Elder DE, Elenitsas R, Johnson BL Jr, Ioffreda M, et al. Lever´s histopathology of the skin. 9th ed. Philadelphia: Lippincott Williams and Wilkins. 2005;pp:101-7.

5. Gisondi P, Tessari G, Conti A, Piaserico S, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157(1):68-73.

6. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007;25(6):529-34.

7. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298(7):321-8.

8. Pearce DJ, Morrison AE, Higgins KB, Crane MM, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005;16(5-6):319-23.

9. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004;150(5):917-28.

10. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141(2):185-91.

11. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210(3):194-9.

12. Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol 2004;151(2):381-7.

13. Llamas-Esperón G, Poletti ED, Muñoz-Sandoval R, Serna-Vela FJ y col. Factores de riesgo cardiovascular en pacientes con psoriasis. Póster presentado en el XXV Congreso Nacional de Cardiología, XII Congreso Latino de Cardiología y Cirugía Cardiovascular Pediátrica. Sociedad Mexicana de Cardiología. Boca del Río, Ver. México 24 a 28 de noviembre, 2007.

14. Neimann AL, Shin DB, Wang X, Margolis DJ, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829-35.

15. Gelfand JM, Neimann AL, Shin DB, Wang X, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41.

16. Malerba M, Gisondi P, Radaeli A, Sala R, et al. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006;155(6):1165-9.

17. Ludwig RJ, Herzog C, Rostock A, Orchsendorf FR, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156(2):271-6.

18. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol 2007;56(6):901-16.

19. Zamboni S, Zanetti G, Grosso G, Ambrosio GB, et al. Dietary behavior in psoriatic patients. Acta Derm Venereol Suppl (Stockh) 1989;146:182-3.

20. Higa-Sansone G, Szomstein S, Soto F, Brasecsco O, et al. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004;14(8):1132-4.

21. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141(12):1527-34.

22. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999;135(12):1490-3.

23. Pietrzak A, Lecewicz-Torun B, Kadziela-Wypyska G. Changes in the digestive system in patients suffering from psoriasis. Ann Univ Mariae Cruie Sklodowska 1998;53:187-94.

24. Lea WA Jr, Cornish HH, Block WD. Studies on serum lipids, proteins, and lipoproteins in psoriasis. J Invest Dermatol 1958;30(4):181-5.

25. Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venerol 2007;21(10):1330-32.

26. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54(4):614-21.

27. Opie LH. Metabolic syndrome. Circulation 2007;115(3):32-35.

28. Shapiro J, Cohen AD, David M, Hodak E, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007;56(4):629-34.

29. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005;12(6):295-300.

30. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111(11):1448-54.

31. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157(6):1249-51.

32. Sergeant A, Makrygeorgou A, Chan WC, Thorrat A, Burden D. C-reactive protein in psoriasis. Br J Dermatol 2008;158(2):417-9.